AZ rejigs endpoints in key trial of durvalumab
Health systems should fund more treatments for chronic diseases, says EFPIA
Afinitor finally recommended after rejection in 2011.
Sales of Humira could peak above $18 billion – CEO
California’s Kite strikes deals with Fosun and Daiichi Sankyo.
Biotech specialises in autoimmune disorder drugs.
Frazier takes swipe at price-hiking generics firms.
Merrimack sells off Onivyde and generic cancer drug